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Abstract
Dysregulation of Ras and Rho family small GTPases drives the invasion and metastasis of multiple cancers. For their
biological functions, these GTPases require proper subcellular localization to cellular membranes, which is regulated by a
series of post-translational modifications that result in either farnesylation or geranylgeranylation of the C-terminal CAAX
motif. This concept provided the rationale for targeting farnesyltransferase (FTase) and geranylgeranyltransferases (GGTase)
for cancer treatment. However, the resulting prenyl transferase inhibitors have not performed well in the clinic due to issues
with alternative prenylation and toxicity. As an alternative, we have developed a unique class of potential anti-cancer
therapeutics called Prenyl Function Inhibitors (PFIs), which are farnesol or geranyl-geraniol analogs that act as alternate
substrates for FTase or GGTase. Here, we test the ability of our lead PFIs, anilinogeraniol (AGOH) and anilinofarnesol (AFOH),
to block the invasion of breast cancer cells. We found that AGOH treatment effectively decreased invasion of MDA-MB-231
cells in a two-dimensional (2D) invasion assay at 100 mM while it blocked invasive growth in three-dimensional (3D) culture
model at as little as 20 mM. Notably, the effect of AGOH on 3D invasive growth was phenocopied by electroporation of cells
with C3 exotransferase. To determine if RhoA and RhoC were direct targets of AGOH, we performed Rho activity assays in
MDA-MB-231 and MDA-MB-468 cells and found that AGOH blocked RhoA and RhoC activation in response to LPA and EGF
stimulation. Notably, the geranylgeraniol analog AFOH was more potent than AGOH in inhibiting RhoA and RhoC activation
and invasive growth. Interestingly, neither AGOH nor AFOH impacted 3D growth of MCF10A cells. Collectively, this study
demonstrates that AGOH and AFOH dramatically inhibit breast cancer invasion, at least in part by blocking Rho function,
thus, suggesting that targeting prenylation by using PFIs may offer a promising mechanism for treatment of invasive breast
cancer.
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Introduction
Breast cancer is the second leading cause of cancer-related
deaths among women due to invasion and metastasis [1]. Despite
the progress made in prevention, detection, diagnosis and
treatment in recent years, more than 70% of breast cancer
patients with invasion and metastases still succumb to their disease
within 5 years of diagnosis [2]. Therefore, a more effective strategy
for treating breast cancer invasion and metastasis is needed.
Dysregulation of small GTPases such as Ras and Rho family
GTPases (RhoA, RhoC, Rac1 and Cdc42) is critical to drive the
invasion and metastasis of a variety of cancers, including breast
carcinomas. Rho small GTPases belong to the Ras superfamily
and consist of at least 20 members of 20–30 KDa GTP-binding
proteins in mammalian cells [3]. The Rho subgroup of Rho
GTPases consists of RhoA, RhoB, and RhoC proteins, which
share about 85% amino acid sequence identity [4]. Substantial
evidence supports the involvement of aberrant expression of Rho
and elevated Rho activity in the metastasis capacity of different
types of cancers such as breast, colon, prostate, lung, head and
neck, and pancreatic cancers [5–8]. Indeed, RhoA and RhoC
have been shown to be involved in different stages of tumor
progression such as loss of cell polarity and cell junctions,
intravasation and vascularization [5].
Like Ras, Rho GTPases act as molecular switches in many
cellular processes and cycle from GDP-bound inactive state to the
GTP-bound active state. The cycling between these two states is
controlled by guanine nucleotide-exchange factors (GEFs),
GTPase activating proteins (GAPs), and guanine nucleotide-
dissociation inhibitors (GDIs) [3]. To enable this cycle to occur,
Rho proteins require a series of post-translational modifications,
with the first and most critical step being covalent attachment of
an isoprenoid group to the cysteine residue in the carboxyl-
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terminal CAAX motif (where C represents cysteine, A represents
primarily aliphatic amino acids and X represents any amino acid
which direct the type of prenylation). This prenylation process
includes farnesylation and geranylgeranylation [9]. Specifically,
RhoA and RhoC are exclusively geranylgeranylated and RhoB is
either geranylgeranylated or farnesylated [9]. Ultimately, active
Rho proteins, through binding to their effectors, are involved in a
variety of cellular events, including gene regulation, cell cycle
progression, migration and transformation [10]. Based on its
regulation and functional mode, several strategies targeting Rho
signaling modules, such as inhibition of Rho protein-GEF
interaction, inactivation of Rho effectors as well as inhibition of
lipid modification, have been employed [7]. For example,
farnesyltransferase inhibitors (FTI) and geranylgeranyltransferase
(GGTase) inhibitors (GGTI) have been used to target Rho
prenylation [11,12]. However, the efficacy, specificity and toxicity
of this approach remain a challenge.
We have developed a unique class of potential anti-cancer
agents called Prenyl Function Inhibitors (PFIs), which are farnesol
or geranylgeraniol analogs that act as alternative substrates for
FTase and GGTase. Our previous studies have shown that these
unnatural FPP analogs are effective alternative substrates for
mammalian FTase. Our lead PFI, anilinogeraniol (AGOH), is the
alcohol precursor of 8-anilinogeranyl diphosphate (AGPP), which
is incorporated into cellular protein in an FTase and GGTase
dependent manner [13,14]. Notably, in combination with two-
dimensional (2D) electrophoresis and immunoblotting, we found
that AGOH also labels Rho small GTPases, including RhoA,
RhoB and RhoC, in statin treated myeloid leukemia cell lines [14].
These findings prompted us to investigate the use of PFIs to target
Rho GTPases as potential therapeutics for the treatment of breast
cancer. Here, we report the effect of two lead PFIs, AGOH and
AFOH, on breast cancer cell invasion and provide rationale for
the use of PFIs in targeting Rho to combat breast cancer.
Materials and Methods
Cell Lines and Reagents
MDA-MB-231 cells were obtained from American Type
Culture Collection (ATCC) and were cultured in low-glucose
DMEM. MDA-MB-468 cells [15] were obtained from Janet Price
(MD Anderson, University of Texas, Houston, TX) and main-
tained in DMEM/F12 (1:1). These two cell lines were cultured
with 10% FBS and 1% penicillin/streptomycin/glutamine (Life
Technologies). Immortalized non-malignant human breast epi-
thelial MCF10A cell line was obtained from ATCC and
maintained in DMEM/F12 media with 5% horse serum
supplemented with 20 ng/ml EGF, 10 mg/ml insulin, 0.5 mg/ml
hydrocortisone, 100 ng/ml Cholera toxin and 1% penicillin/
streptomycin/glutamine. AGOH and AFOH were synthesized as
described previously [16,17]. The relationship between these
compounds and the natural isoprenoids is illustrated in Figure 1.
Matrigel Invasion Assay
Matrigel (10 mg, BD Biosciences) was dried onto the upper well
of Transwell chambers (6.5-mm diameter, 8-mm pore size,
Corning Life Sciences). One hour before assay, the Matrigel was
reconstituted with 100 ml medium and the bottom chamber was
coated with 15 mg/ml collagen I. Cells (70% confluent) were
trypsinized, rinsed three times with medium plus 250 mg/ml BSA
in the presence of AGOH or AFOH at indicated concentration.
Cells (56104) were added to the top wells, and medium/BSA
containing 5 ng/ml EGF plus 250 ng/ml insulin was added to the
bottom wells; cells were allowed to invade for 5 hrs at 37uC. Non-
invaded cells were removed from the top chamber using a cotton
swab; invaded cells on the bottom of the Transwell insert were
fixed with 100% methanol and stained with 1% crystal violet. Four
fields per well were counted and averaged, and the data were
presented as the mean number of cells invaded per mm2+/2
standard deviation from triplicate determinations.
Three-dimensional (3D) Culture and
Immunofluorescence Staining
3D culture for MDA-MB-231 cells and MCF10A cells were
performed as described previously [18,19]. Briefly, MDA-MB-231
cells (56103) in 200 ml of T4 cell medium (DMEM/F12 medium
with 5 ng/ml EGF, 250 ng/ml insulin, 10 mg/ml transferrin,
2.6 ng/ml sodium selenite, 1.4 mM hydrocortisone and 5 mg/ml
prolactin) were seeded onto solidified growth factor reduced
Matrigel (BD Biosciences; 100 ml per well of 8-well chamber slide)
and then covered with 200 ml of 10% Matrigel containing
medium. For MCF10A cells, cells (56103) were resuspended in
assay medium (DMEM/F12 medium with 2% horse serum, 5 ng/
ml EGF, 10 mg/ml insulin, 1.4 mM hydrocortisone, 100 ng/ml
Cholera toxin and 1% penicillin/streptomycin/glutamine) plus
2% Matrigel and plated on the top of solidified growth factor
reduced Matrigel. The next day, DMSO, AGOH or AFOH at
indicated concentration were added to the cultures and fresh
compound added every 4 days for MCF10A cells and every other
day for MDA-MB-231 cells. When MCF10A cells were cultured in
3D for 14 days or MDA-MB-231 control cells developed an
invasive growth phenotype (approximately 6–8 days), phase
contrast images of randomly chosen fields were taken with a
Nikon Ti-E inverted microscope using Nikon Elements software.
Then 20–40 ml of Matrigel containing colonies for each condition
were smeared onto a slide, fixed with 4% paraformaldehyde (for F-
Figure 1. Prenyl Function Inhibitors. Structure relationship
between natural isoprenoids (A) and lead PFIs (B).
doi:10.1371/journal.pone.0089892.g001
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actin staining using TRITC-Phalloidin {Sigma}) or cold Metha-
nol/Acetone (1:1), permeabilized and immunostained using the
following antibodies: a6 integrin antibody (rat anti-human CD49f,
EMD Millipore), mouse anti-E-cadherin (BD Biosciences), Cy2-
conjugated goat anti-rat IgG or Cy3-conjugated donkey anti-
mouse IgG (Jackson ImmunoResearch). Slides were mounted in
VECTASHIELD mounting medium for fluorescence (Vector
Laboratories, Inc.). Confocal images were captured with an
Olympus FV1000 confocal microscope using a 606UPlanS Apo
NA 1.35 oil objective and FV10-ASW2 software.
GST and C3 Protein Electroporation
For C3 exotransferase treatment, MDA-MB-231 cells (36106)
were electroporated at 450 V and 25 mF with 5 mg of bacterially
expressed glutathione-S-transferase (GST) or GST-C3 exotrans-
ferase purified protein (expression vectors provided by Dr. Keith
Figure 2. AGOH inhibits MDA-MB-231 cells invasion. (A) MDA-MB-231 cells were treated with AGOH at the indicated concentration and then
assessed for Matrigel invasion toward the combination of 5 ng/ml EGF and 250 ng/ml insulin. (B) Cells treated with AGOH for 3 days were harvested
in RIPA buffer, immunoblotted with polyAG-antibody. Asterisk (*) symbolizes a p value ,0.05. These results are representative from at least three
separate experiments.
doi:10.1371/journal.pone.0089892.g002
Figure 3. AGOH inhibits 3D invasive growth of MDA-MB-231 cells. MDA-MB-231 cells were seeded in Matrigel and treated with AGOH at the
indicated concentration. After culturing for 8 days, phase contrast images were taken from randomly chosen fields (A, C, E) or Matrigel containing
colonies were fixed and immunostained for F-actin (phalloidin, red) and nuclei (DAPI, blue) (B, D). The representative images from three separate
experiments are shown. Scale bars represent 50 mm.
doi:10.1371/journal.pone.0089892.g003
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Burridge, University of North Carolina, Chapel Hill, NC) as
described previously [20]. Cells were then incubated with 5 mg/ml
polymyxin B nonapeptide hydrochloride (Sigma) for 15 min,
rinsed, and then seeded into 3D culture. To test the efficiency and
specificity of C3 treatment, cells were harvested for RhoA or Rac1
activity as described below.
Activity Assays for Small GTPases
GST-Rhotekin Rho binding domain (RBD) binding assay was
used to assess Rho activity, as described previously [21,22]. For
these experiments, MDA-MB-231 and MDA-MB-468 cells were
grown to 70% confluence while being treated with AGOH,
AFOH or DMSO for 3 days. Then, cells were trypsinized, and
rinsed with medium plus 250 mg/ml BSA in the presence of
AGOH, AFOH or DMSO, as appropriate, at indicated concen-
trations. Cells (36106) were plated onto 60-mm dishes coated with
collagen I (50 mg/ml in PBS, coated overnight) with the presence
of AGOH, AFOH or DMSO for 2 hrs before they were treated
with indicated chemoattractants (100 nM LPA {Sigma} or 5 ng/
ml EGF {Preprotech}) for 5 min and harvested with Rho lysis
buffer (50 mM Tris, pH 7.2, 500 mM NaCl, 1% Triton X-100,
0.25% sodium deoxycholate, 0.1% sodium dodecylsulfate (SDS),
10 mM MgCl2, 10 mg/ml protease inhibitor cocktail and 1 mM
phenylmethylsulfonyl fluoride). Cleared extracts were incubated
for 30 min at 4uC with glutathione beads (GE Healthcare Life
Sciences) coupled with GST-Rhotekin RBD fusion protein at 4uC
and then washed 3 times with Rho activity assay wash buffer
(50 mM Tris, pH 7.2, 150 mM NaCl, 1% Triton X-100, 10 mM
MgCl2, plus protease inhibitors). Rho content of beads eluents and
lysate controls were separated by 15% SDS–polyacrylamide gel
electrophoresis (PAGE), transferred to an Immobilon-PSQ PVDF
transfer membrane (EMD Millipore) and immunoblotted with
mouse anti-RhoA antibody (Santa Cruz Biotechnologies) or mouse
anti-RhoC antibody (Abcam).
For Rac and Ras assays, cells were treated as described above.
For Rac assays, cells were electroporated with GST or GST-C3 as
Figure 4. Rho GTPases are required for the invasive growth of
MDA-MB-231 cells. Cells were electroporated with 5 mg GST or GST-
C3 exotransferase, then seeded in 3D Matrigel and imaged (A) as
described in Figure 3, or assessed for RhoA (B) and Rac1 (C) activities as
described in the Methods section.
doi:10.1371/journal.pone.0089892.g004
Figure 5. AGOH blocks RhoA and RhoC activation in response to LPA. MDA-MB-231 cells (A and E) or MDA-MB-468 cells (B) were treated
with 100 mM AGOH for 3 days, plated on collagen I coated dishes in the presence of PFI and then treated with 100 nM LPA or 5 ng/ml EGF as
indicated for 5 min before harvesting for RhoA (A and B, quantified in C and D) or RhoC (E, quantified in F) activity assay. Rho activity assays are
representative from at least three separate experiments.
doi:10.1371/journal.pone.0089892.g005
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described above. Cell lysates were harvested with Rac lysis buffer
(50 mM Tris, pH 7.4, 100 mM NaCl, 1% NP-40, 10% glycerol,
2 mM MgCl2, plus protease inhibitors), clarified by centrifugation,
and then incubated with Pak1 Rac/cdc42-binding domain-GST
fusion protein bound to glutathione beads for 30 min at 4uC, as
described previously [20]. For Ras activity assays, cells were
treated with DMSO or 100 mM AGOH as described for the Rho
activity assays and then stimulated with EGF. Cell lysates were
harvested with Ras lysis buffer (50 mM Tris pH 7.4, 150 mM
NaCl, 2.5 mM MgCl, 1% NP-40, 0.5 mM PMSF and 10 mg/ml
protease inhibitor cocktail) and incubated with glutathione beads
coupled with GST-RalGDS-Ras binding domain-fusion protein at
4uC for 1 hr, as described [23]. For both assays, beads then were
washed with lysis buffer for 3 times, and GTP-bound Rac or Ras
content of the beads, as well as protein content of lysate controls,
were determined by separating proteins by 15% SDS-PAGE and
immunoblotting with anti Rac-1 monoclonal antibody (BD
Biosciences) or anti-K-Ras antibody (Abcam), respectively.
Immunoblotting
Cells were treated with PFIs or DMSO solvent control in
normal culturing conditions at indicated concentrations for 3 days
prior to harvesting with RIPA buffer containing protease
inhibitors. Total cell lysates (80 mg) were separated by 15%
SDS-PAGE and probed with rabbit sera against the anilinogeranyl
moiety as describe previously [13]. For p-MLC assay, cells were
plated in collagen I coated dishes for 2 hrs before stimulation with
100 nM LPA for 5 min. Then cells were harvested in RIPA buffer
with phosphatase inhibitors (150 mM NaCl, 0.5 mM EGTA,
0.5% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 50 mM
Tris-HCl pH 7.4, 15 mg/ml protease inhibitor cocktail, 1 mM
PMSF, 50 mM NaF and 10 mM sodium pyrophosphate). Then,
total cell lysates (80 mg) were subjected to 15% SDS-PAGE,
transferred to PVDF membrane and immunoblotted with p-MLC
S19 (Cell Signaling Technology) or total myosin light chain 2
antibody (Cell Signaling Technology). b-actin (monoclonal anti-
body; Sigma) was used as the loading control.
Figure 6. AFOH blocks RhoA and RhoC activation in response to LPA or EGF. MDA-MB-231 cells (A, C, E and F) or MDA-MB-468 cells (B and
D) were treated with AFOH at the indicated concentration for 3 days, plated on collagen I coated dishes in the presence of AFOH and then treated
with 100 nM LPA (A and E, quantified in C and F) or 5 ng/ml EGF (B, quantified in D) for 5 min prior to harvesting for RhoA (A–D) or RhoC (E, F) activity
assays. Rho activity assays are representative from at least three separate experiments.
doi:10.1371/journal.pone.0089892.g006
Figure 7. PFIs block p-MLC downstream of Rho signaling in
MDA-MB-231 cells. MDA-MB-231 cells were treated with 100 mM
AGOH and 20 mM AFOH for 3 days, plated on collagen I coated dishes,
and then treated with 100 nM LPA for 5 min. Cell lysates were
immunoblotted with p-MLC. Total MLC-2 and b-actin serve as the
loading controls.
doi:10.1371/journal.pone.0089892.g007
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Results
Lead PFI Compound AGOH Inhibits MDA-MB-231 Cell
Invasion
Previous studies demonstrated that AGOH is a pro-drug version
of the FPP analog AGPP and is incorporated into normally
prenylated cellular proteins in an FTase and GGTase dependent
manner [14,16,24,25]. Growth factors such as EGF and insulin
are critical for mammary gland morphogenesis, serve as the
important survival factors of mammary epithelial cells [26], and
are used in 3D invasive growth assays [18,27]. We sought to make
the invasion assay as close as possible to the 3D assay and tested
the effects of components of the T4 medium (used for 3D culture)
in the transwell invasion assay. We observed that the combination
of EGF and insulin displayed a synergistic effect on the invasive
potential of MDA-MB-231 cells and closely mimicked results from
the complete T4 medium (data not shown). To determine how
PFIs impact invasion, we treated MDA-MB-231 cells in 2D
culture with 20 mM or 100 mMAGOH for 3 days, then performed
Matrigel invasion assays toward the combination of 5 ng/ml EGF
plus 250 ng/ml insulin. We found that AGOH inhibited invasion
of MDA-MB-231 cells at concentration of 100 mM compared to
control cells. In contrast, at 20 mM, AGOH did not have
significant effects (Figure 2A). To confirm AGOH was incorpo-
rated into proteins, MDA-MB-231 cell lysates were immuno-
blotted for anilinogeranyl (AG) modified cellular proteins using a
high affinity rabbit anti-sera specific for the anilinogeranyl moiety
(Figure 2B) [13]. Consistent with previous studies [28,29], we
found that a broad range of bands (molecular weight from 17–
100 KD) correlated well with known prenylated proteins appeared
in the AGOH treated samples compared to DMSO control. In
addition, the pattern of mid-range molecular weight proteins that
incorporated AGOH correspond to farnesylated nuclear lamins
(Figure 2B), similar to those found in other cell types [28].
AGOH Inhibits MDA-MB-231 Cells Invasive Growth in 3D
Culture
Culturing cells in 3D is commonly used to assess the
physiologically relevant morphogenesis and invasive potential of
breast epithelial and cancer cells [18,30]. Accordingly, we next
investigated the effect of AGOH on 3D invasive growth. In
contrast to the 2D invasion assay, treatment of MDA-MB-231 cells
in 3D culture with 20 mM AGOH showed a significant reduction
in invasive growth (Figure 3A and C). This effect is even more
dramatic at 100 mM where live colonies were difficult to find
(Figure 3E). The immunocytochemistry staining revealed that
DMSO-treated cells developed invasive growth (Figure 3B);
however, cells treated with 20 mM AGOH lost their invasive
potential in 3D culture (Figure 3D). Surprisingly, Ras activities in
these cells were not affected (Figure S1), suggesting that Ras was
not the primary target for AGOH in these breast cancer cells.
Figure 8. AFOH blocks 3D invasive growth of MDA-MB-231 cells. Cells were seeded in growth factor reduced Matrigel, treated with DMSO (A,
B) or 5 mM AFOH (C, D) for 10 days. Then phase contrast images were taken from randomly chosen fields (A, C). Colonies grown in Matrigel were
smeared onto slides, immunostained for F-actin (red) and nuclei (blue), and then imaged by confocal microscopy (B, D). The representative images
from three experiments are shown.
doi:10.1371/journal.pone.0089892.g008
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Rho GTPases are Required for MDA-MB-231 Cells Invasive
Growth
Tumor invasive growth is a complex, multistep program
involving in the interplay of tumor cells and the microenviron-
ment, and in turn tumor cells acquiring the propensity for
migration, invasion and proliferation [31]. Rho signaling is
engaged in at least two distinct types of motility in 3D matrix:
Rho/ROCK-dependent amoeboid motility and Rac-dependent
mesenchymal motility [32]. To test whether Rho is required for
the invasive growth of MDA-MB-231 cells, cells were electropo-
rated with 5 mg GST or GST-C3 exotransferase, which inactivates
RhoA, RhoB and RhoC by ADP ribosylation. These results
demonstrated that C3 treatment phenocopies AGOH treatment
(Figure 4A), suggesting that Rho GTPases are required for the
invasive growth of MDA-MB-231 cells. Cells were also assayed for
Rho (Figure 4B) and Rac (Figure 4C) activities to ensure the
efficiency and specificity of C3 on Rho activity. The activity assays
showed that C3 efficiently blocked active Rho but had no effect on
Rac activity. These data suggest that AGOH may affect the
invasive potential of MDA-MB-231 cells by modifying Rho
signaling.
Rho Activity is Inhibited by AGOH
To test whether Rho activity is affected by AGOH, we
performed GST-Rhotekin RBD pull down assay to assess the
activity of Rho. We treated MDA-MB-231 cells with AGOH for 3
days, then cells were seeded onto collagen-coated dishes for 2 hrs
in the presence of 100 mM AGOH before treatment with 100 nM
LPA for 5 min. Results from the Rho activity assay showed that
LPA stimulated Rho activity; however, AGOH at 100 mM
significantly blocked active RhoA to the basal level (Figure 5A
and C). We also found that AGOH inhibited RhoA activity in
MDA-MB-468 cells in response to 5 ng/ml EGF (Figure 5B and
D), thus confirming that this effect was not cell type or growth
factor specific. In addition, RhoA activity of MDA-MB-231 cells
treated with AGOH and stimulated with 10% serum provided
similar results (data not shown), further supporting the inhibitory
effect of AGOH on Rho.
The Rho subgroup contains three isoforms: RhoA, RhoB and
RhoC. Previous studies demonstrated that RhoB is poorly
expressed in MDA-MB-231 cells [33]. RhoC plays an important
role in tumor metastasis [8,34] and is considered a biomarker for
invasive breast cancer [35]. To determine the effect of AGOH on
RhoC, we immunoblotted GST-Rhotekin RBD pull down assay
with an anti-RhoC antibody. Our results demonstrated that
AGOH also blocked the activity of RhoC in response to LPA in
MDA-MB-231 cells (Figure 5E and F). Taken together, the data
support a mechanism by which AGOH inhibits the invasive
potential of breast cancer cells, at least in part, through inhibition
of RhoA and RhoC activity.
AFOH is more Potent than AGOH in Inhibiting Rho
Activity and 3D Invasive Growth
AGOH enters cells through the plasma membrane and is
phosphorylated in sequential kinase reactions leading to AGPP,
which is a substrate analog of FPP preferentially utilized by FTase
Figure 9. AGOH and AFOH do not affect 3D growth of MCF10A cells. MCF10A were seeded in Matrigel and treated with AGOH and AFOH at
the indicated concentrations for 14 days. Then the phase contrast images (A) were taken from randomly chosen fields. Matrigel-containing colonies
were smeared and immunostained for integrin a6 (green), E-cadherin (red) and nuclei (blue) (B). Diameter of 60–80 individual colonies was measured
and averaged in each condition (C). Cells were treated with AGOH for 3 days, harvested in RIPA buffer, and immunoblotted with polyAG antibody (D).
Representative images from at least three separate experiments are shown. Scale bars in phase contrast equal 50 mm and in confocal images
represent 20 mm.
doi:10.1371/journal.pone.0089892.g009
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[13]. Notably, RhoA and RhoC are normally geranylgeranylated
by GGTase-1. We have found that AGPP can also be converted to
AFPP, a substrate analog of GGPP preferentially utilized by
GGTase I to modify cellular proteins [36]. We hypothesized that
treatment with the geranylgeraniol analog AFOH would be more
potent at inhibiting Rho and breast carcinoma invasion than
AGOH.
To test this concept, MDA-MB-231 cells were treated with
various concentrations of the geranylgeraniol analog AFOH for 3
days prior to assessing Rho activity. As shown in Figure 6A and C,
RhoA activity stimulated by LPA displayed a dose-dependent
inhibition with AFOH treatment. AFOH inhibited RhoA at
concentrations as low as 10 mM, which was 10 times more potent
compared to AGOH under the same conditions (Figure 5A and
C). The similar potency was also observed in MDA-MB-468 cells
in response to EGF (Figure 6B and D). Importantly, RhoC activity
was also inhibited (Figure 6E and F). To confirm RhoA and RhoC
activities were inhibited by PFIs, we further tested the level of
phosphorylation of myosin light chain (p-MLC) downstream of
Rho/ROCK signaling pathway. As shown in Figure 7, AGOH
and AFOH significantly blocked the phosphorylation of MLC in
MDA-MB-231 cells in response to LPA stimulation. Accordingly,
MDA-MB-231 cells treated with AFOH in 3D culture showed a
dramatic inhibition of invasive growth at concentrations between
1 mM to 5 mM (Figure 8A–D). Collectively, the data further
demonstrated that RhoA and RhoC are targets of PFIs in breast
cancer cells.
The Lead PFIs AGOH and AFOH do not Affect MCF10A 3D
Growth
To test whether these drugs have any toxicity to non-malignant
cells, we treated MCF10A cells in 3D culture with the indicated
PFIs starting on Day 1 until harvested on Day 14. As shown in
Figure 9, DMSO-treated control MCF10A cells formed round,
small, well-organized acinar-like structures. Interestingly, AGOH
and AFOH treatment did not produce significant difference in
terms of colony size, organization of acinar structures or the
overall number of colonies (Figure 9A–C). Notably, AGOH was
incorporated efficiently into MCF10A cellular proteins (Figure 9D)
at levels similar to MDA-MB-231 cells, suggesting that this effect
was not due to the lack of efficiency of PFIs incorporation in
MCF10A cells. We concluded from these experiments that our
lead PFIs, especially AFOH, were able to target Rho and block
invasive growth of malignant breast cancer cells with minimal
toxicity to the normal cells.
Discussion
Rho signaling is important for actin cytoskeleton reorganization,
focal adhesion formation, and cell migration. Accordingly, Rho
proteins, in particular RhoA and RhoC, play critical roles in
tumor invasion and metastasis in a variety of cancers including
breast cancer [37–40]. Therefore, RhoA and RhoC are consid-
ered to be valuable therapeutic targets. Rho proteins, however,
have not been considered ‘‘druggable’’ by conventional therapeu-
tics since the Ras superfamily of small GTPases are globular in
structure with limited surface sites suitable for small molecule
binding [41]. Therefore, current strategies for targeting Rho
involve interfering upstream regulators as well as downstream
effectors of Rho signal transduction. These strategies include
inhibition of Rho prenylation by blocking the mevalonate pathway
with statins [42,43] or with by FTIs and/or GGTIs [12], directly
suppressing Rho by siRNA or bacterial toxin C3, and blocking
downstream effectors such as ROCK [7,44]. A recently developed
strategy involves the small molecule Rhosin, which interferes with
the interaction of Rho and its GEF [45]. Of these strategies, only
inhibition of protein prenylation has been tested clinically for the
treatment of cancer.
Prenylation of Rho and most other Ras superfamily small
GTPases is obligatory for their biological function. Targeting
protein prenylation has received considerable attention, which
resulted in the generation of FTIs and GGTIs. Initial FTI clinical
trials in breast cancer showed substantial responsiveness; however,
notable toxicity and the inability of FTIs to yield clear survival
benefits halted these trials. The lack of FTI efficacy is attributed to
alternative prenylation of proteins (such as K-Ras) by GGTase-I
when FTase is inhibited and their inability to block geranylger-
anylated proteins, such as Rho GTPases [43].
To circumvent these hurdles, we developed the PFI class of
unnatural synthetic isoprenoids that act as the alternative FTase
and/or GGTase substrates. The lead PFIs, AGOH and AFOH,
are pro-drug structural analogs of the respective preferred
substrates for FTase (FPP) and GGTase (GGPP). In cells, the
PFIs are converted to their corresponding diphosphates and are
transferred by FTase and GGTase to CAAX substrates. In MDA-
MB-231 cells, PFIs inhibited invasion in both 2D and 3D and
blocked RhoA and RhoC activation in response to growth factors.
Moreover, the PFIs showed no overt cytotoxicity in non-malignant
MCF10A cells at concentrations that blocked colony formation
and invasive growth of the MDA-MB-231 cells in 3D culture.
Thus, the PFIs, such as AGOH and AFOH, represent a new class
of molecules for the inhibition of Rho proteins that can be further
developed as potential anti-metastatic agents.
In our study, we uncovered multiple variables that impact how
PFIs could be screened, which have important implications for
drug development. First, we found that cells grown under the
more physiological 3D condition are more sensitive to PFIs than in
2D culture condition. This observation indicates that using 2D cell
culture for library screening could miss potentially effective
compounds based on the lack of proper physiological context
and cellular architecture, as has been previously suggested [46–
48]. Second, the lead geranylgeraniol derivative AFOH is more
potent than the farnesol derivative AGOH in inhibiting the
invasive potential of MDA-MB-231 cells and blocking the
activation of RhoA and RhoC in response to growth factors.
These differences are likely due to the need for AGOH to be
elongated to AFOH, which occurs with low efficiency, in order for
it to be an efficient GGTase substrate [36]. In contrast, AFOH
acts as a more direct substrate for GGTase. The enhanced potency
of AFOH may be due to the greater importance of geranylger-
anylated proteins compared to farnesylated proteins in breast
cancer cell invasion. Third, these two lead compounds did not
exhibit significant toxicity for MCF10A cells in 3D culture, even at
concentrations that completely inhibited invasive growth of MDA-
MB-231 cells. This finding is particularly interesting considering
the challenge of developing drugs that target Rho with acceptable
toxicity. Our data showed that this effect is not due to the failure of
PFIs to incorporate into cellular proteins in MCF10A cells. A
better explanation for the lack of impact of PFIs on MCF10A cells
is that RhoA and RhoC are dispensable for acinar formation and
cell growth control in non-malignant cells such as MCF10A. In
support of the concept that Rho proteins are needed for the
malignant transformation of MCF10A cells, a recent study
demonstrated that overexpression of constitutively active RhoC
G14V in MCF10A cells increased lung metastasis in mice [49].
We demonstrated that RhoA and RhoC are PFI targets that are
essential for the invasive potential of breast cancer cells. Our data
(Figure 4) clearly verified that Rho proteins are critical for the
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invasive potential of MDA-MB-231 cells in 3D culture, which is in
accordance with other studies [50,51]. However, we cannot rule
out the possibility that PFI activity is also due to the involvement of
other geranylgeranylated proteins. The Ras family proteins such as
Rap and Ral are also geranylgeranylated. In fact, Ral signaling has
been shown to be important in the regulation of LPA–mediated
migration and invasion in MDA-MB-231 cells [52]. In addition,
we found that RalA and RalB were labeled with anti-AG
polyclonal antibody in myeloid leukemia cell lines by using 2D
electrophoresis in conjunction with immunoblotting [14]. There-
fore, it is likely that RhoA and RhoC represent a subset of proteins
important for tumor cell invasion that are affected by PFIs and
that protein prenylation in general remains the primary target of
PFIs.
In summary, our study demonstrates that hijacking the activity
of FTase and GGTase to modify proteins with alternative prenyl
donors is a viable strategy for targeting Rho activity in cells that is
effective in blocking the invasive potential of breast carcinoma
cells. Therefore, our results validate the concept that PFIs provide
a promising mechanism of targeting Rho for the treatment of
breast cancer. The discovery that PFIs have anti-Rho activity
provides new impetus to target and block the function of protein
prenyl groups.
Supporting Information
Figure S1 AGOH does not affect Ras activity. MDA-MB-
231 cells were treated with 100 mM AGOH or DMSO for 3 days,
plated on collagen I coated dishes, and then treated with 5 ng/ml
EGF for 5 min in the presence of AGOH or DMSO, as indicated,
prior to harvesting for K-Ras activity, as described in the Materials
and Methods section.
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